Among the other compounds, fostamatinib is a SYK inhibitor involved in B-cell and innate immune cell activation, and has been tested in RA clinical trials with positive outcomes (Tanaka et al. 2021). The gene discussed is SYK; the disease is rheumatoid arthritis.